Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.46 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.45 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.45 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | LAP3 | P28838 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9398462 | 0.98 | S1PR2 (0.48) | OPRM1S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL28114426 | 0.93 | — | — | |
| SCHEMBL5520840 | 0.83 | — | — | |
| SCHEMBL28002842 | 0.78 | S1PR2 (0.52) | OPRM1S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL6542341 | 0.77 | GSR (0.40) | LMNABLM | |
| SCHEMBL672857 | 0.77 | OPRM1 (0.63) | OPRM1S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL8726615 | 0.76 | — | — | |
| SCHEMBL9425652 | 0.76 | LMNA (0.46) | OPRM1SPHK1LMNAMAPTGPR84 | |
| SCHEMBL24042540 | 0.76 | PLA2G1B (0.48) | OPRM1S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL27611846 | 0.76 | PLA2G1B (0.48) | OPRM1S1PR2S1PR1S1PR3S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110274651-A1 | Noscapine and Noscapine Analogs and Their Use in treating Infectious Diseases by Tubulin Binding Inhibition | EMORY UNIVERSITY (US) | 2011-11-10 | — | — | US | disclosed |
| EP-2328578-A2 | NOSCAPINE AND NOSCAPINE ANALOGS AND THEIR USE IN TREATING INFECTIOUS DISEASES BY TUBULIN BINDING INHIBITION | Emory University (US) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010030582-A2 | NOSCAPINE AND NOSCAPINE ANALOGS AND THEIR USE IN TREATING INFECTIOUS DISEASES BY TUBULIN BINDING INHIBITION | EMORY UNIVERSITY (US) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110274651-A1 | Noscapine and Noscapine Analogs and Their Use in treating Infectious Diseases by Tubulin Binding Inhibition | NOS1, NOS2, TBCA | OPRM1 2140/4885S1PR2 4347/4885S1PR1 3647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.